• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
    • 7.1.2 Health
      • 7.1.2.1 2005
      • 7.1.2.2 2006
      • 7.1.2.3 2007
  • 7.2 Photos & Logos

New Publication on Alzheimer’s Disease Shows Patients with Behavioral Disturbances Benefit from Axura® (Memantine)

Frankfurt am Main, 10.05.2005

Alzheimer’s disease is mostly associated with cognitive impairments, in particular the loss of short-term memory. In the initial stage of the disease this is in fact the most prominent symptom. But starting in the moderate stage of the disease, non-cognitive symptoms like functional adverse events and behavioral symptoms are dominant.

These distinct behavioral symptoms can appear in the form of mood swings, anxiety, psychotic episodes, strong agitation, and aggression and are far more challenging for both patients as well as families and caregivers. They often lead to placement in a nursing home because the demands of the patient’s difficult behavior are more than the family and caregivers can manage.¹

According to a recent study conducted by S. Gauthier and associates that was just published in the International Journal of Geriatric Psychiatry, challenging behavioral symptoms like these - in particular agitation and aggression - can be positively influenced by therapy with Axura® (active ingredient: Memantine).² This is not only expected to relieve the burden on patients and all caregivers, but potentially also delays the need to place patients in nursing homes.

In addition to these data, economic healthcare advantages and cost savings of Memantine therapy have been shown in earlier publications.³.

References:

1 Ferris S.H. et al. (1987):
Institutionalization of Alzheimer`s disease patients:reducing precipitating factors through family counselling. Home Health Care Serv Q 8: 23 - 51

2 Gauthier S., Wirth Y. Möbius H.J. (2005):
Effects of memantine in behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies

3 Wimo A. et al. (2003):
Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 21: 327-340

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s